ライフサイエンスコーパス: chemotherapy

1 inclusion in the trial (and thus just before chemotherapy).

2 ale human treatment campaigns, or preventive chemotherapy.

3 ncrease the efficacy of NAMPT inhibitors and chemotherapy.

4 n of apoptosis allows many cancers to resist chemotherapy.

5 ease relapse after 5-FU-based gastric cancer chemotherapy.

6 following progression on platinum-containing chemotherapy.

7 at includes surgery, radiation, and systemic chemotherapy.

8 metastases with liver-dominant disease after chemotherapy.

9 with poor outcome and attenuated response to chemotherapy.

10 13 renders ovarian cancer cells resistant to chemotherapy.

11 mit this common side-effect of many types of chemotherapy.

12 ts with R/R HL an alternative to traditional chemotherapy.

13 intenance of the HIV DNA reservoir following chemotherapy.

14 d (vi) may have no role in responsiveness to chemotherapy.

15 be used to select patients for perioperative chemotherapy.

16 Cisplatin-based chemotherapy.

17 ression-free survival compared with that for chemotherapy.

18 ry (OAC) alone versus OAC with intravitreous chemotherapy.

19 kaemia who were not candidates for intensive chemotherapy.

20 onal strategy to conventional tumor-directed chemotherapy.

21 ter when deciding for adjuvant or palliative chemotherapy.

22 y was done within 4-6 weeks of completion of chemotherapy.

23 vity of these targets restore sensitivity to chemotherapy.

24 he final 14 days of life, 357 (10%) received chemotherapy.

25 eatment SIRT concurrent with cycle 1 or 2 of chemotherapy.

26 survival after DNA damage-inducing platinum chemotherapy.

27 trial of women with breast cancer undergoing chemotherapy.

28 ts a promising strategy to potentiate cancer chemotherapy.

29 bit strong synergistic effects with standard chemotherapy.

30 cancer specimens from patients treated with chemotherapy.

31 grew after each subsequent cycle of repeated chemotherapy.

32 m decisions on withholding adjuvant systemic chemotherapy.

33 arising in most tumors following exposure to chemotherapy.

34 higher rates compared to repeat dosing with chemotherapy.

35 infection and the efficacy of antimony (Sb) chemotherapy.

36 evasion of apoptosis and tumor resistance to chemotherapy.

37 hair loss at 4 weeks after the last dose of chemotherapy.

38 oxidative damage should improve tuberculosis chemotherapies.

39 After induction chemotherapy 163 of 189 (84.0%) underwent definitive sur

40 nts; 115 (50%) to ceritinib and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to doceta

41 evaluating >/=12 lymph nodes (LNs), adjuvant chemotherapy (AC) for stage III patients, and AC within

42 Effectiveness of adjuvant chemotherapy according to time to initiation after surge

43 he most successful drugs ever used in cancer chemotherapy, acting against a variety of cancer types.

44 Failing to complete chemotherapy adversely affects survival in patients with

45 d retention may increase the potency of this chemotherapy agent and allow for reduced systemic doses.

46 Low-risk intravenous chemotherapy agents had overuse that continued to decrea

47 Anti-cancer therapies including chemotherapy aim to induce tumour cell death.

48 survival was 50.3% (95% CI 45.5-54.9) in the chemotherapy alone group and 48.1% (43.2-52.7) in the ch

49 nts included anastomotic leaks (30 events in chemotherapy alone group vs 69 in the chemotherapy plus

50 nts with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in

51 apy plus bevacizumab groups (8.4 months) and chemotherapy-alone groups (7.1 months; 0.83 [0.66-1.05];

52 bevacizumab groups versus 13.3 months in the chemotherapy-alone groups (hazard ratio 0.77 [95% CI 0.6

53 enrolled 452 patients (225 [50%] in the two chemotherapy-alone groups and 227 [50%] in the two chemo

54 nificant improvement in OS compared with the chemotherapy-alone groups: 16.8 months in the chemothera

55 amycin), bleomycin, vinblastine, dacarbazine chemotherapy along with involved-field radiotherapy (25

56 leading to cellular resistance to cytotoxic chemotherapies and ionizing radiation.

57 and low birth weight included treatment with chemotherapy and a diagnosis of breast cancer, non-Hodgk

58 concept experiments that compare response to chemotherapy and biological therapies between patients a

59 te-mediated nanomedicines and nanoprobes for chemotherapy and diagnostics with an emphasis on in vivo

60 re aggressive diseases with poor response to chemotherapy and dismal survival.

61 and by the British Society for Antimicrobial Chemotherapy and from the Cambridge University Hospitals

62 rs that progressed after at least 2 lines of chemotherapy and had no further curative options.

63 t of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy.

64 cal outcomes and may predict the efficacy of chemotherapy and human epidermal growth factor receptor

65 y be 1 of the few cancers for which multiple chemotherapy and nonchemotherapy regimens are considered

66 should thus be considered standard high-dose chemotherapy and ongoing randomised studies will continu

67 Concurrent chemotherapy and PBT to treat unresectable NSCLC afford

68 isease, organ-preservation surgery, combined chemotherapy and radiation, or radiation alone offer the

69 Genotoxicity-induced hair loss from chemotherapy and radiotherapy is often encountered in ca

70 nd to sensitize cancer cells to conventional chemotherapy and radiotherapy, and the potential to over

71 carcinogenesis and cancer cell's response to chemotherapy and radiotherapy, little is known about the

72 oxic regions which are resistant to standard chemotherapy and radiotherapy.

73 at least a lobectomy followed by multiagent chemotherapy and radiotherapy; cohort one included patie

74 as independent of the use of modern systemic chemotherapy and remained in propensity score analysis.

75 utations in patients undergoing preoperative chemotherapy and resection for colorectal liver metastas

76 LSCs, which are resistant to chemotherapy and serve as reservoirs for relapse, showed

77 ly to benefit from these drugs combined with chemotherapy and we aimed to explore the activity of cet

78 ich are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted

79 tion dose was 70 Gy, 84% received concurrent chemotherapy, and 27% had pre-existing cardiac disease.

80 e treated for lymphoma, received combination chemotherapy, and did not develop therapy-related myeloi

81 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persisten

82 ns health-related QOL compared with that for chemotherapy, and might represent a new first-line stand

83 Cancer-directed surgery, chemotherapy, and radiation therapy were independently a

84 sing clinical strategies, including modified chemotherapy approaches targeting the DNA damage respons

85 ssess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleura

86 the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment.

87 ts might be well suited to treatment without chemotherapy at all.

88 otherapy plus bevacizumab; IQR 40.8-59.3 for chemotherapy), at which point 415 patients had died (214

89 ast cancer patients treated with neoadjuvant chemotherapy, BCSS and OS were associated with approxima

90 derwent breast MR imaging before neoadjuvant chemotherapy between April 10, 2008, and March 12, 2015.

91 and was not evident after a single cycle of chemotherapy but grew after each subsequent cycle of rep

92 populations that had been equally exposed to chemotherapy but had never been senescent.

93 mmunotherapy, radiotherapy, or 'immunogenic' chemotherapy by leveraging responses to tumor neoantigen

94 tive adjuvants to standard antiacanthamoebal chemotherapy by potentially abrogating virulence-enhanci

95 was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photograph

96 drugs evolves in a patient, highly effective chemotherapy can fail, threatening patient health and li

97 Patients were stratified by chemotherapy centre, site of tumour, and tumour stage.

98 during CD4+ T-cell reconstitution following chemotherapy cessation.

99 cells from terminally ill mice treated with chemotherapy (chemoAML) had higher lipid content, increa

100 Although nurse-led chemotherapy clinics have been set up to address this, t

101 ographic study of nurses' roles in nurse-led chemotherapy clinics, including semi-structured intervie

102 ical areas within the UK operating nurse-led chemotherapy clinics.

103 to predict Kaplan-Meier survival curves for chemotherapy combined with radiation in Non-Small Cell L

104 sitivity to both platinum and PARP inhibitor chemotherapy compared to Trp53 (-/-).

105 Neoadjuvant chemotherapy comprising cisplatin, doxorubicin, and meth

106 The low-dose chemotherapy conditioning regimen depleted blood lymphoc

107 as a mechanism of resistance to DNA-damaging chemotherapy, consistent with a local loss of DDR, and i

108 Patients receiving chemotherapy could cross over to receive nivolumab at th

109 ntional prognostic factors to guide adjuvant chemotherapy (CT) decisions.

110 tinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R).

111 While chemotherapy delivery by nanocarriers has modestly impro

112 data suggest that inflammatory responses to chemotherapy depend on time-of-day and are tissue specif

113 hic response followed by surgery and further chemotherapy determined by histology.

114 ion of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparagina

115 Cumulative chemotherapy doses correlated significantly with MR imag

116 Platinum-based chemotherapy doublets are a standard of care for women w

117 ergized with the frontline colorectal cancer chemotherapy drug irinotecan.

118 The severe adverse effect from chemotherapy drug is a leading cause for the patients to

119 Doxorubicin, a first-line chemotherapy drug, often causes myelosuppression in pati

120 Co-delivery of both chemotherapy drugs and siRNA from a single delivery vehi

121 rug conjugates carrying synergistic pairs of chemotherapy drugs can be used to reduce drug administra

122 ed that combinations of nonchemotherapy plus chemotherapy drugs can impact outcomes, whereas data wit

123 on long periods of unhindered growth without chemotherapy drugs present and was not evident after a s

124 sm, including those involved in metabolizing chemotherapy drugs that are commonly used in the treatme

125 pensity-matched pairs, patients who received chemotherapy during the later interval had a lower morta

126 he sample included 678220 adults who started chemotherapy during the observation period.

127 studies suggest that intra-peritoneal (i.p.) chemotherapy effectively treats residual EOC after cyto-

128 Among patients with TNBC who received chemotherapy, elevated ITGB4 expression was associated w

129 nges similar to those encountered in the pre-chemotherapy era, including the inability to cure tuberc

130 going commonly used genotoxic (DNA-damaging) chemotherapy experience an accelerated loss of the ovari

131 OSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19

132 and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis.

133 y assigned (1:1) to either oxaliplatin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxal

134 The lack of effective chemotherapies for high-grade serous ovarian cancers (HG

135 d multifocal disease (80% vs 56%, P = 0.04), chemotherapy for AS (58% vs 22%, P < 0.01), margin-negat

136 CTP as a drug target to enhance conventional chemotherapy for cancer patients with high levels of TCT

137 reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC).

138 CV genotype 1b-positive subjects, undergoing chemotherapy for DLBCL, were enrolled between June 2015

139 undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of s

140 acebo after completion of first-line/initial chemotherapy for metastatic disease.

141 es transurethral resection of bladder tumor, chemotherapy for radiation sensitization, and external b

142 Patients who had received chemotherapy for recurrence and those with non-healing w

143 who did not have progressive disease during chemotherapy (four to eight cycles) were randomly assign

144 on criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour PTEN status.

145 ng the duration and intensity of neoadjuvant chemotherapy further improved survival compared with the

146 l, 65%-99.1%) for the OAC plus intravitreous chemotherapy group (P = 0.05).

147 hich point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus beva

148 %] in the ceritinib group vs 12 [11%] in the chemotherapy group).

149 higher in the blinatumomab group than in the chemotherapy group, both with respect to complete remiss

150 omab group and in 92% of the patients in the chemotherapy group.

151 ficantly worse in the OAC plus intravitreous chemotherapy group.

152 Targeted therapy trials vs chemotherapy had an OS HR of 0.98 (95% CI, 0.80-1.19) an

153 ic adenocarcinoma for whom gemcitabine-based chemotherapy had failed were randomized to selumetinib p

154 Those receiving adjuvant chemotherapy had modestly higher doses ( P = .002), but

155 perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival

156 Chemotherapy has been shown to enrich cancer stem cells

157 Here, we show that CAFs exposed to chemotherapy have an active role in regulating the survi

158 breast cancer patients receiving neoadjuvant chemotherapy have no increased risk for surgical morbidi

159 gery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal cancers can be assoc

160 en these people are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies fo

161 antagonism synergizes with paclitaxel based chemotherapies in patient-derived xenograft models (PDX)

162 herapeutic index of current standard-of-care chemotherapies in preclinical models of advanced pancrea

163 proves outcomes when added to platinum-based chemotherapy in advanced-stage non-squamous NSCLC.

164 uptake before the initiation of doxorubicin chemotherapy in HD patients may predict the development

165 The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted an

166 ing endothelial LPP enhances the efficacy of chemotherapy in ovarian cancer.

167 ed to explore the activity of cetuximab with chemotherapy in patients with advanced NSCLC who are EGF

168 ponse to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, pla

169 Notch pathway inhibitors in combination with chemotherapy in select patients with small-cell lung can

170 erapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contr

171 tive epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Council Adjuvant Ga

172 ) has been shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients

173 nd safety of ceritinib versus platinum-based chemotherapy in these patients.

174 e efficacious treatment option compared with chemotherapy in this patient population.

175 sociated with better response to neoadjuvant chemotherapy in TNBC (P < 0.0001) but not in non-TNBC pa

176 high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leuk

177 on-mutilating surgery, and minimal-morbidity chemotherapy (in the case of tumour progression)-for pae

178 er when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic feat

179 eatment subclones that become dominant after chemotherapy, indicating selection for resistance phenot

180 Conversely, radiation therapy and chemotherapy induce DNA damage to drive cells into apopt

181 previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been lim

182 ccumulation of extracellular ATP /AMP during chemotherapy-induced apoptosis in Jurkat human leukemia

183 n HD patients may predict the development of chemotherapy-induced cardiotoxicity, suggesting that pro

184 t gut microbiota promotes the development of chemotherapy-induced mechanical hyperalgesia.

185 Antiemetics are used to prevent chemotherapy-induced nausea and vomiting in patients wit

186 receiving intravenous chemotherapy with high chemotherapy-induced nausea and vomiting risk (32.4% [n

187 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced neuropathic pain produced by paclit

188 ical target for prevention of chronic cancer chemotherapy-induced neuropathic pain.

189 Chemotherapy-induced peripheral neuropathy (CIPN) is a c

190 v1.7 are increased in a preclinical model of chemotherapy-induced peripheral neuropathy (CIPN), the m

191 an acute myeloid leukemia (AML) that enabled chemotherapy-induced regressions of established disease

192 Here we investigated whether chemotherapy-induced senescence could change stem-cell-r

193 rely survive >6 months even following active chemotherapy interventions.

194 disease have improved outcomes when adjuvant chemotherapy is administered before, rather than concurr

195 Early response to induction chemotherapy is an important prognostic factor in B-lymp

196 Anthracycline-based chemotherapy is associated with dose-dependent, irrevers

197 Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among

198 Cisplatin chemotherapy is commonly used to treat cancer despite se

199 Tuberculosis chemotherapy is dependent on the use of the antibiotic p

200 olves in the face of radiation and cytotoxic chemotherapy is just beginning to be understood as a maj

201 The current chemotherapy is limited only to nifurtimox and benznidaz

202 Effective chemotherapy is not available.

203 uals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use.

204 ded; if NSCLC lacks the T790M mutation, then chemotherapy is recommended.

205 Although trastuzumab plus chemotherapy is the standard of care for first-line trea

206 xane(R) is now considered a gold standard in chemotherapy, its 21% response rate leaves much room for

207 up D eyes treated initially with intravenous chemotherapy (IVC) and followed up for at least 1 year f

208 Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial.

209 The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cancer has raised

210 matic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prost

211 confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC.

212 tumor markers as predictors of prognosis in chemotherapy-naive patients with advanced NSCLC, we recr

213 Chemotherapy-naive patients with metastatic colorectal c

214 Patients and Methods Chemotherapy-naive patients with unresectable, nonsarcom

215 itivity or resistance to taxanes in men with chemotherapy-naive, metastatic, castration-resistant pro

216 Adjuvant chemotherapy offers a survival benefit to a number of st

217 e is known about the impact of cytoreductive chemotherapy on HIV-1 reservoir dynamics, persistence, a

218 group were poor and often involved prolonged chemotherapy; on NWTS-5, 4-year EFS for all children wit

219 f care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 mo

220 enroll in hospice and more likely to receive chemotherapy or be admitted to intensive care units at t

221 explore the effect surgery interaction with chemotherapy or radiation therapy on survival by using t

222 ound when limiting the analysis to rituximab chemotherapy (OR = 0.19, 95% CI 0.11-0.32) and lymphoma

223 ory or newborn screening, use of preparative chemotherapy, or the type of donor used, did not impact

224 urrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treatment-naiv

225 the treatment of neuropathic pain, including chemotherapy (paclitaxel)-induced neuropathic pain.SIGNI

226 of four), to receive atezolizumab 1200 mg or chemotherapy (physician's choice: vinflunine 320 mg/m(2)

227 apy alone group and 48.1% (43.2-52.7) in the chemotherapy plus bevacizumab group (hazard ratio [HR] 1

228 nts in chemotherapy alone group vs 69 in the chemotherapy plus bevacizumab group), and infections wit

229 214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group).

230 was not significantly different between the chemotherapy plus bevacizumab groups (8.4 months) and ch

231 The chemotherapy plus bevacizumab groups continued to show s

232 hemotherapy-alone groups: 16.8 months in the chemotherapy plus bevacizumab groups versus 13.3 months

233 herapy-alone groups and 227 [50%] in the two chemotherapy plus bevacizumab groups).

234 s in each treatment group (IQR 41.5-62.2 for chemotherapy plus bevacizumab; IQR 40.8-59.3 for chemoth

235 usion, combining lestaurtinib with intensive chemotherapy proved feasible in younger patients with ne

236 year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were

237 More advanced disease may require chemotherapy, radiotherapy, and lymph node dissection.

238 yngectomy after radiotherapy with or without chemotherapy, reconstruction with vascularised tissue re

239 ho had received rituximab in addition to the chemotherapy regimen (hazard ratio, 3.3; 95% CI, 1.0-14.

240 effects were related to the lymphodepleting chemotherapy regimen and included lymphopenia, neutropen

241 sion on or after one previous platinum-based chemotherapy regimen in the metastatic setting.

242 Choosing the optimal chemotherapy regimen is still an unmet medical need for

243 All patients received the same chemotherapy regimen of bortezomib and dexamethasone.

244 Subset analyses evaluating histology, chemotherapy regimen, and incremental COX-2 expression d

245 dition to their planned cisplatin-containing chemotherapy regimen, using permuted blocks of four.

246 tive trials are needed to define the optimal chemotherapy regimen.

247 n essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia (AML).

248 chieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients

249 eceived at least two previous platinum-based chemotherapy regimens, had achieved complete or partial

250 who will receive one of the widely-accepted chemotherapy regimens.

251 rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, and death.

252 tive plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are ve

253 re we illustrate how such conditions promote chemotherapy resistance in pancreatic ductal adenocarcin

254 varian cancers (HGS-OvCa) frequently develop chemotherapy resistance.

255 ulnerability that might be exploited to kill chemotherapy-resistant acute myeloid leukemia cells.

256 h potential therapeutic applications against chemotherapy-resistant AML.Significance: These findings

257 inatorial approaches to improve treatment of chemotherapy-resistant SCCs.

258 ere associated with approximated subtype and chemotherapy response and were lowest in TNBC patients w

259 However, chemotherapy response is typically transient and patient

260 When comparing matched pre- and post-chemotherapy samples from 10 cases, the mutational signa

261 s with PNAs decreased invasion and increased chemotherapy sensitivity.

262 e II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, le

263 umanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients

264 day or BAT (which could include ruxolitinib, chemotherapy, steroids, no treatment, or other standard

265 gher doses ( P = .002), but patients with no chemotherapy still had doses equivalent to five tablets

266 mics of tumor evolution with cisplatin-based chemotherapy, suggest mechanisms of clinical resistance,

267 iculties up to 6 months after treatment with chemotherapy than do age-matched noncancer controls.

268 s for enhanced lymphoid-specific combination chemotherapies that have the potential to overcome treat

269 susceptibility of old fibroblasts to IR and chemotherapy that can be mitigated by GC4419.

270 s moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy

271 men (given sequentially vs concurrently with chemotherapy), then implemented centrally via an interac

272 dynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids; however

273 illier (NK) cells in addition to gemcitabine chemotherapy to prevent tumor recurrence.

274 in the QLQ-LC13 composite endpoint than did chemotherapy-treated patients (46 [31%] of 151 patients

275 ts, n = 14; median age, 8.4 months) received chemotherapy: two courses of topotecan plus vincristine

276 f tumour-infiltrating immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metasta

277 SETTINGS: Four chemotherapy units/cancer centres in the UK Purposive sa

278 21-gene assay resulted in a net decrease in chemotherapy use of 23%.

279 They were treated with 3-drug induction chemotherapy (vincristine, dactinomycin, and doxorubicin

280 iotherapy, systemic chemotherapy, or topical chemotherapy) vs treatment-naive BCCs.

281 d 10.7% were Asian; and the mean duration of chemotherapy was 2.3 months (median, 2.1 months).

282 Median overall survival from the start of chemotherapy was 29 months (95% CI 24-40 months).

283 Chemotherapy was administered for at least 24 weeks foll

284 Chemotherapy was determined by histology: carboplatin pl

285 noma who had progressed after platinum-based chemotherapy were randomly assigned (1:1), via an intera

286 effectiveness and cost-benefit of preventive chemotherapy were very promising, and this was robust ov

287 ytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not.

288 Chemotherapy with a fluorinated pyrimidine and a platinu

289 esults support the option for dose-dense PTX chemotherapy with active single doses, showing the relat

290 In advanced disease, chemotherapy with anthracyclines and/or ifosfamide, trab

291 ence of feedback as an indication to combine chemotherapy with approaches that limit the process of t

292 cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients with advanced

293 Lymphodepletion chemotherapy with CD19-targeted chimeric antigen recepto

294 treated in a randomised trial of front-line chemotherapy with cyclophosphamide, doxorubicin, vincris

295 neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant fol

296 hest rates among those receiving intravenous chemotherapy with high chemotherapy-induced nausea and v

297 Consolidation involved chemotherapy with or without hematopoietic stem cell tra

298 tocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant tr

299 ctionation within the context of concomitant chemotherapy with the inclusion of new trials.

300 4) was observed with a deleterious effect of chemotherapy with TP53/KRAS comutations versus WT/WT (ha